IngentaConnect Long-Term Tolerability of Fexofenadine in Healthy Volunteers

Authors: Nathan R.A.¹; Mason J.²; Bernstein D.I.³; Howland W.C.I.⁴; Kaiser H.B.⁵; Meltzer E.O.⁶; Segall N.⁷

Source: Clinical Drug Investigation, Volume 18, Number 4, 1 October 1999 , pp. 317-328(12)

Abstract:

Objective: To evaluate the long-term safety of fexofenadine compared with placebo.

Design: Two placebo-controlled, double-blind, randomised, parallel-group studies.

Setting: Twenty-nine investigational centres in the USA.

Patients: Healthy volunteers aged 12 to 65 years.

Interventions: In a 6-month study, 436 volunteers received either fexofenadine 60mg twice daily or placebo; in a 12-month study, 477 volunteers received fexofenadine 240mg once daily or placebo.

Main Outcome Measures and Results: In both studies, adverse events, 12-lead ECGs, laboratory evaluations and vital signs were recorded. There was no statistically significant difference in the incidence of adverse events when fexofenadine was compared with placebo. The most frequently reported treatment-related adverse event was headache, which occurred with a similar incidence for fexofenadine compared with placebo in both studies. Fexofenadine was not associated with statistically significant changes in 12-lead ECGs or clinically relevant changes in laboratory evaluations or vital signs when compared with placebo.

Conclusions: These two long-term studies demonstrate that fexofenadine, at doses up to 240mg once daily for up to 12 months in healthy volunteers, is safe and well tolerated.

Keywords: Fexofenadine, pharmacodynamics; Fexofenadine, adverse-reactions; Randomised-controlled-trials

Document Type: Original article

Affiliations: 1: Asthma and Allergy Associate and Research Center, Colorado Springs, Colorado, USA 2: Hoechst Marion Roussel, Kansas City, Missouri, USA 3: University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA 4: HealthQuest Therapy and Research Institute, Inc., Austin, Texas, USA 5: University of Minnesota Medical School, Minneapolis, Minnesota, USA 6: Allergy and Asthma Medical Group and Research Center, San Diego, California, USA 7: Allergy & Asthma Clinic, Atlanta, Georgia, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$62.95 plus tax Refund Policy